Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine

Annals of Neurology

Volumn 64, Issue 2, 2008, Pages 200-211

  Morrell, Martha J ^a,b   Hayes, Frances J ^c   Sluss, Patrick M ^c   Adams, Judith M ^c   Bhatt, Mohit ^d   Ozkara, Cigdem ^e   Warnock, Clay R ^f   Isojärvi, Jouko ^g,h  

^a STANFORD UNIVERSITY   (United States)

^b Neuropace   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^e ISTANBUL UNIVERSITY   (Turkey)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF OULU   (Finland)

^h UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLUCURONIDE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PREGNANEDIOL; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; ALOPECIA; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HORMONE URINE LEVEL; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; MENARCHE; MENSTRUAL CYCLE; MONOTHERAPY; NAUSEA; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; ANOVULATION; EPILEPSY; FEMALE; HUMANS; HYPERANDROGENISM; INTERNATIONALITY; OVULATION; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TRIAZINES; VALPROIC ACID;

EID: 51549118694     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21411     Document Type: Article

References (32)

1. Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980;21:261-271.
2. Herzog AG, Seibelmm, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346.
3. Webber MP, Hauser WA, Ottman R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia 1986;27:746-752.
4. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
5. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-711.
6. Artama M, Isojärvi J, Raitanen J, Auvinen A. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004;159:1057-1063.
7. Taylor A. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-902.
8. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risk. Endocrinol Metab Clin North Am 1999;28:247-264.
9. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997;20:519-526.
10. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
11. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;44:444-450.
12. Betts T, Yarrow H, Dutton N, et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003;12: 323-329.
13. Isojärvi JIT, Taubøll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate treated women. Am J Med 2001;111:290-296.
14. Mikkonen K, Vainionpä ä LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004;62:445-450.
15. Morrell M, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-199.
16. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
17. Munro CJ, Stabenfeldt GH, Cragun JR, et al. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. Clin Chem 1991;37:838-844.
18. Lasley BL, Lohstroh P, Kuo A, et al. Laboratory methods for evaluating early pregnancy loss in an industry-based population. Am J Ind Med 1995;28:771-781.
19. Adams J, Polson DW, Frank S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293:355-359.
20. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Meriiam GR, eds. Polycystic ovary syndrome. Oxford: Blackwell Scientific, 1992:377-384.
21. Norman AW, Litwack G. Estrogens and progestins. Hormones. London: Academic Press, 1997:361-386.
22. Knockenhauer ES, Key TJ, Kashar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
23. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
24. Diamanti-Kaundarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
25. Herzog AG, Seibel MM, Schomer D, et al. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 1984;34:1389-1393.
26. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-619.
27. Rättyä J, Pakarinen AJ, Knip M, et al. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001;57:440-444.
28. Tauboll E, Wojtowicz AK, Ropstad E, Gregoraszczuk EL. Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro. Reprod Toxicol 2002;16:319-325.
29. Tauboll E, Gregoraszczuk EL, Kolodziej A, et al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003;44:1014-1021.
30. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004;145:799-808.
31. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59: 1078-1086.
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.